Dingemans, Anne-Marie C.

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J. M., McRae, S. E., Widder, J., Feng, L., et al. (2015) · The Lancet Oncology

Lung Cancer Diagnosis and TreatmentAdvanced Radiotherapy Techniques

Cited by 1,462

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 619

Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)

De Ruysscher, D., Wanders, R., van Baardwijk, A., Dingemans, A.-M. C., Reymen, B., Houben, R., Bootsma, G., Pitz, C., van Eijsden, L., Geraedts, W., et al. (2012) · Journal of Thoracic Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 283

Virtual reality and artificial intelligence for 3-dimensional planning of lung segmentectomies

Sadeghi, A. H., Maat, A. P. W. M., Taverne, Y. J. H. J., Cornelissen, R., Dingemans, A.-M. C., Bogers, A. J. J. C., & Mahtab, E. A. F. (2021) · JTCVS Techniques

Anatomy and Medical TechnologyAugmented Reality Applications

Cited by 89

Induction of peripheral effector CD8 T-cell proliferation by combination of paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer patients

de Goeje, P. L., Poncin, M., Bezemer, K., Kaijen-Lambers, M. E. H., Groen, H. J. M., Smit, E. F., Dingemans, A.-M. C., Kunert, A., Hendriks, R. W., & Aerts, J. G. J. V. (2019) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersLung Cancer Research Studies

Cited by 43

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

Johnson, M. L., de Langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., et al. (2022) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 39

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib

Ernst, S. M., van Marion, R., Atmodimedjo, P. N., de Jonge, E., Mathijssen, R. H. J., Paats, M. S., de Bruijn, P., Koolen, S. L., von der Thüsen, J. H., Aerts, J. G. J. V., et al. (2024) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 24

9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)

Menis, J., Bironzo, P., Radj, G., Greillier, L., Monnet, I., Livi, L., Young, R., Decroisette, C., Cloarec, N., Robinet, G., et al. (2020) · Annals of Oncology

Lung Cancer Research StudiesLung Cancer Diagnosis and Treatment

Cited by 2